{"id":1850,"date":"2023-04-18T16:45:00","date_gmt":"2023-04-18T14:45:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1850"},"modified":"2024-08-01T14:13:29","modified_gmt":"2024-08-01T12:13:29","slug":"26d-liecivo-atezolizumab-tecentriq-v-kombinacii-s-bevacizumabom-na-liecbu-dospelych-pacientov-s-hepatocelularnym-karcinomom","status":"publish","type":"post","link":"https:\/\/www.niho.sk\/en\/26d-liecivo-atezolizumab-tecentriq-v-kombinacii-s-bevacizumabom-na-liecbu-dospelych-pacientov-s-hepatocelularnym-karcinomom\/","title":{"rendered":"26D: Lie\u010divo atezolizumab (Tecentriq) v kombin\u00e1cii s bevacizumabom na lie\u010dbu dospel\u00fdch pacientov s hepatocelul\u00e1rnym karcin\u00f3mom"},"content":{"rendered":"<ol class=\"wp-block-list\">\n<li><strong>Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Hepatocelul\u00e1rny karcin\u00f3m (HCC) v pokro\u010dilom \u0161t\u00e1diu je v s\u00fa\u010dasnosti nekurat\u00edvne ochorenie, ktor\u00e9 vytv\u00e1ra ve\u013ek\u00fa z\u00e1\u0165a\u017e na pacientov po fyzickej aj psychickej str\u00e1nke a skracuje ich o\u010dak\u00e1van\u00e9 pre\u017e\u00edvanie. Aktu\u00e1lne hraden\u00e1 lie\u010dba pokro\u010dil\u00e9ho alebo neresekovate\u013en\u00e9ho HCC nezodpoved\u00e1 najnov\u0161\u00edm medzin\u00e1rodn\u00fdm \u0161tandardom.<\/p>\n\n\n\n<ol start=\"2\" class=\"wp-block-list\">\n<li><strong>O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Tecentriq je liek proti rakovine, ktor\u00fd obsahuje lie\u010divo atezolizumab. Atezolizumab patr\u00ed do skupiny liekov naz\u00fdvanej monoklon\u00e1lne protil\u00e1tky. Monoklon\u00e1lna protil\u00e1tka je typ bielkoviny vytvorenej tak, aby rozpoznala a naviazala sa na \u0161pecifick\u00fd cie\u013e v tele. T\u00e1to protil\u00e1tka m\u00f4\u017ee pom\u00f4c\u0165 v\u00e1\u0161mu imunitn\u00e9mu syst\u00e9mu bojova\u0165 proti rakovine.<\/p>\n\n\n\n<p>Tento liek bol pre predmetn\u00fa indik\u00e1ciu registrovan\u00fd v Eur\u00f3pskej \u00fanii v septembri 2020.<\/p>\n\n\n\n<ol start=\"3\" class=\"wp-block-list\">\n<li><strong>Ako sa na atezolizumab pozeraj\u00fa odborn\u00edci?\u00a0<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Klinick\u00fd odborn\u00edk sa vyjadril, \u017ee na Slovensku s\u00fa\u010dasn\u00e1 lie\u010dba HCC nie je v s\u00falade s najnov\u0161\u00edmi medzin\u00e1rodn\u00fdmi odpor\u00fa\u010daniami ke\u010f\u017ee ch\u00fdbaj\u00fa nov\u00e9 lie\u010diva ako Tecentriq. U lek\u00e1rov pracuj\u00facich s HCC pacientmi m\u00f4\u017ee nekategorizovanie Tecentriqu podpori\u0165 frustr\u00e1ciu zo zaost\u00e1vania za najlep\u0161\u00edm \u0161tandardom.<\/p>\n\n\n\n<ol start=\"4\" class=\"wp-block-list\">\n<li><strong>\u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Dr\u017eite\u013e registr\u00e1cie (Roche Registration GmbH (DEU)) podal \u017eiados\u0165 o zaradenie lieku Tecentriq (lie\u010divo atezolizumab) do \u00fahrad z verejn\u00e9ho zdravotn\u00e9ho poistenia pri pou\u017eit\u00ed v kombin\u00e1cii s bevacizumabom na lie\u010dbu dospel\u00fdch pacientov s hepatocelul\u00e1rnym karcin\u00f3mom.<\/p>\n\n\n\n<p class=\"has-custom-highlight-background-color has-background\">NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Tecentriq v predmetnej indik\u00e1ci\u00ed, pokia\u013e:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list has-custom-highlight-background-color has-background\">\n<li>pr\u00edde k zmene indika\u010dn\u00e9ho obmedzenia,<\/li>\n\n\n\n<li>dr\u017eite\u013e registr\u00e1cie uprav\u00ed po\u017eadovan\u00fa v\u00fd\u0161ku \u00fahrady tak, aby sp\u013a\u0148ala krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti a&nbsp;<\/li>\n\n\n\n<li>z d\u00f4vodu strednej miery neistoty dr\u017eite\u013e registr\u00e1cie poskytne dodato\u010dn\u00fa z\u013eavu. Neistota je spojen\u00e1 predov\u0161etk\u00fdm s odhadom dlhodob\u00e9ho pr\u00ednosu.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Tecentriq v predmetnej indik\u00e1ci\u00ed, pokia\u013e&#8230;<\/p>","protected":false},"author":3,"featured_media":1844,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[89,88],"class_list":["post-1850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-atezolizumab","tag-tecentriq"],"_links":{"self":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1850"}],"version-history":[{"count":0,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1850\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media\/1844"}],"wp:attachment":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}